AdvaMed members manufacture and ship instruments and high-quality tests that, together with key inputs from our colleagues across the testing ecosystem (e.g., PPE, plastics, swabs, etc.), serve as the backbone of supply for the U.S. testing response to COVID.

AdvaMed has created a national COVID-19 Diagnostic Supply Registry to support state and federal governments in their pandemic responses. AdvaMed and its members are fully committed to providing key data to policymakers and the public in our collective work mobilizing against the pandemic.

AdvaMed is leading this data tracking and analysis effort, driven by thirteen leading diagnostic manufacturers whose tests together comprise ~75-80% of the COVID-19 Molecular IVD tests on the market in the U.S.

**Key Data-Driven Summary of the U.S. COVID Testing Supply**

*Based on data as of September 24th, 2022*

- Across leading COVID diagnostic manufacturers, ~888 million molecular COVID-19 tests have been shipped since March 2020, including ~680 million commercial tests and ~208 million extraction reagents.
- Registry participants collectively shipped ~3.0 million molecular tests for the week ending September 24th.
- Daily Molecular tests run for the week ending September 24th increased by 5% compared to the previous week, with an average of ~0.5 million tests per day last week.
- Additionally: laboratory-based Serology/Antibody and Antigen testing are widely available throughout the U.S., as is point-of-care testing – including over-the-counter home testing.

---

1. Averaged over the week to account for fluctuations by day of the week. State-reported results (molecular test result figures used where available, otherwise total test results used, which may include antigen tests). 2. IVD and LDT molecular diagnostic test shipments to hospital, reference, and other laboratories.